

Product Spotlight

Standardize your drug metabolism studies with the DMET™ Plus Premier Pack

The DMET™ Plus Premier Pack, which includes arrays, reagents, and analysis software, is the most comprehensive, cost-effective product containing known pharmacogenetic markers for drug metabolism studies. It standardizes drug metabolism studies and enables faster discovery and measurement of genetic variation associated with drug response compared to traditional methods. The DMET Plus Panel features markers in all FDA-validated genes and covers more than 90 percent of the current ADME Core markers as defined by the PharmaADME group. Affymetrix developed this content by collaborating with key opinion leaders from both industry and academia.

Key benefits:

- Standardizes ADME content
- Delivers the most biologically relevant, high-value data
- Streamlines workflow for cost effectiveness

Key features:

- 1,936 drug metabolism markers in 225 genes
- Markers in all FDA-validated genes
- More than 90 percent of the ADME Core markers as defined by the PharmaADME group
- Translation table for automated star allele analysis

"The DMET Panel has allowed us to better delineate the stable therapeutic dose of warfarin. Our hope is that these studies will enable us to reduce the overall complications of warfarin therapy by a better prediction of stable therapeutic dose."

Michael Caldwell, MD, PhD, Marshfield Clinic



DMET Plus Premier Pack delivers results

Proven

The high-value, unique content of the DMET Plus Panel enables the identification of significant, new biomarker associations. Warfarin, which is prescribed to prevent heart attacks and strokes, is one of the top 10 drugs known to cause severe adverse events, including drug-related death. In a recent warfarin study using the DMET Plus Panel, researchers discovered a new variant in CYP4F2 (a drug metabolizing enzyme) which explained 8 percent of dosing variability in select patient populations (Caldwell, *et al.*, Blood, 2008). This new biomarker is being tested in a Phase III prospective trial. The discovery was a direct result of our drug metabolism panel-based approach and was missed by other pharmacogenetic approaches.

Fast

With the DMET Plus Premier Pack, you can query 1,936 known ADME markers simultaneously rather than having to run multiple, consecutive experiments. In addition, the translation table included in DMET Console Software automatically translates SNP and non-SNP genotyping results into standardized star allele nomenclature (i.e., CYP2D6*3 or CYP2C19*2), so you can easily integrate your data into existing workflows. This process is completed in minutes rather than days, saving you time and money.

Timely

The DMET Plus Premier Pack is available for use in your lab or through qualified service providers. Please contact your local account manager or email DMET@affymetrix.com for more information.

Specifications

Average call rate	≥ 99%
Average concordance to reference	≥ 99.5%
Average reproducibility	≥ 99.8%

*Specifications are based on the entire comprehensive DMET Plus Panel and apply to passing samples only.

During the development of the DMET Plus Panel, an average sample pass rate in excess of 95 percent was observed, based on the performance of more than 3,500 samples processed by six sites (three external and three internal).

Ordering information

Part number	Description
901268	DMET™ Plus Premier Pack Contains sufficient reagents and arrays to process 42 samples and six controls
901495	DMET™ Plus Starter Pack Contains sufficient reagents and arrays to process seven samples and one control